Trial Profile
An Open-label, Randomized, Single Dose, Four-Period Crossover Study to Compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) With 10% and 15% of Enteric Coated Pellets With Harnal-D Tablets and Harnal Capsules Co-administered With Dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian Ancestry.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Dutasteride/tamsulosin (Primary) ; Dutasteride; Tamsulosin
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 18 Nov 2011 New trial record